Abcuro
Rajeev Shah is a Managing Partner at RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Raj holds a BA from Cornell University, where he majored in Chemistry. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science.
This person is not in the org chart
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.